### SCIENTIFIC DIVISION

#### 43rd MEETING
Milan, IT (2009 4 17-18)

**MINUTES (second draft)**

<table>
<thead>
<tr>
<th>Members:</th>
<th>Abbr.</th>
<th>Term and Time of Office</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauro PANTEGHINI (IT) (Chair)</td>
<td>MP</td>
<td>2nd 2009 01 - 2011 12</td>
</tr>
<tr>
<td>Ian YOUNG (UK) (Vice-Chair)</td>
<td>IY</td>
<td>2nd 2009 01 - 2011 12</td>
</tr>
<tr>
<td>Gary MYERS (US) (Secretary)</td>
<td>GM</td>
<td>1st 2009 01 - 2011 12</td>
</tr>
<tr>
<td>Philippe GILLERY (FR)</td>
<td>PG</td>
<td>2nd 2009 01 - 2011 12</td>
</tr>
<tr>
<td>Lothar SIEKMANN (DE)</td>
<td>LS</td>
<td>2nd 2009 01 - 2011 12</td>
</tr>
<tr>
<td>Naotaka HAMASAKI (JP)</td>
<td>NH</td>
<td>1st 2009 01 - 2011 12</td>
</tr>
<tr>
<td>George BROTEA (US) (Corporate Representative)</td>
<td>GB</td>
<td>1st 2007 01 - 2009 12</td>
</tr>
<tr>
<td>David BUNK (NIST Representative)</td>
<td>DB</td>
<td>Consultant</td>
</tr>
<tr>
<td>Heinz SCHIMMEL (IRMM Representative)</td>
<td>HS</td>
<td>Consultant</td>
</tr>
<tr>
<td>Jean-Claude FOREST (JCTLM Representative)</td>
<td>JCF</td>
<td>Consultant</td>
</tr>
</tbody>
</table>

In attendance: Graham H Beastall (GHB) IFCC President
EXECUTIVE SUMMARY - SCIENTIFIC DIVISION 43rd MEETING, MILAN, ITALY APRIL 17 & 18, 2009.

Present: Mauro Panteghini (Chair), Ian Young (Vice-Chair), Gary Myers (Secretary), Philippe Gillery, Lothar Siekmann, Naotaka Hamasaki and George Brotea (Corporate Representative), David Bunk (NIST Representative), Heinz Schimmel (IRMM Representative) and Jean-Claude Forest (JCTLM Representative) with Ms Paola Bramati (IFCC Office) were in attendance.

6.1 WORLD HEALTH ORGANIZATION (WHO): The WHO Expert Committee on Biological Standardization (ECBS) met in October 2008. The IFCC-NIBSC joint proposal on genetic reference materials is underway.

6.2 CLSI: A total of 22 joint projects involving IFCC have been completed or are underway.

6.22.1 JCTLM: An open call for nominations for JCTLM WG1 Cycle VI and JCTLM WG2 Cycle IV is being made (closing date 30 April 2009). Next meeting of WGs will take place on July 18 before the AACC meeting in Chicago (US).

6.22.2 JCGM: The IFCC is represented in all groups. Mathias Müller is on the Executive Committee. Graham White (AU) is on WG 1 and Francoise Pontet (FR) is on WG 2. The JCGM Executive met on December 2008. JCGM WG 1 met more recently on April 2009. A series of supplements to GUM are currently being prepared.

6.22.3 CCQM: Lothar Siekmann will serve as official IFCC representative and Jean-Claude Forest will serve as alternate representative.

6.31 INSTITUTE FOR REFERENCE MATERIALS AND MEASUREMENTS (IRMM): ERM-DA457/IFCC AST material is available and has been submitted to JCTLM. ERM-DA471/IFCC Cystatin C material remains in characterization phase.

8.2 MAIN ACTIVITIES OF COMMITTEES

8.2.6 C-NPU: On April, 2009 LOINC, NPU, and SNOMED CT began an operational trial of prospective divisions of labor in the generation of laboratory test terminology content. This trial will provide practical experience and important information on opportunities to decrease duplication of efforts in the development of laboratory test terminology and to ensure that SNOMED CT works effectively in combination with either LOINC or NPU.

8.2.11 C-MD: Nominations remain open to join the networks of IFCC Expert Molecular Diagnostics Centres and Member Laboratories. A position paper prepared in conjunction with IRMM on a proposed reference method for DNA sequencing is being circulated.

8.2.13 C-PP: The protocol for transferring values from ERM-DA470k/IFCC to commercial protein assay calibrators has been published.

8.2.19 C-SMCD: The experimental work for the second stage of the project to evaluate BNP, proBNP and NT-proBNP antigens from multiple commercial sources for cross-reactivity in commercial and experimental BNP, NT-proBNP and proBNP assays has been terminated. A manuscript describing the Quality Specifications for Troponin Assays has been reviewed by the SD and submitted to Clinical Chemistry.

8.2.21 C-RSE: The certification process of the AST Reference Material, in cooperation with IRMM, has been terminated. Further discussions on pancreatic lipase standardization issues will occur at Euromedlab 2009 in Innsbruck.

8.2.22 C-POCT: As a result of concern over a lack of productivity by the C-POCT, the IFCC EB decided to terminate the Committee.

8.2.23 C-TLM: Reporting of desirable limits of agreement to laboratories participating in the EQAS for reference laboratories has commenced.

8.2.24 C-RIDL: A review describing the central strategy of the Committee to determine reference intervals using traceable methods was published in the Ann Clin Biochem.
8.3 MAIN ACTIVITIES OF WORKING GROUPS

8.3.3 WG-SEB: As a result of concern over a lack of productivity by the WG-SEB, the IFCC EB decided to terminate the Working Group.

8.3.8 WG-A: The preparation of the new SP3-08 apo B reference material has been completed. SP3-08 validation documentation will be submitted to WHO ECBS.

8.3.16 WG-SHCG: A manuscript titled “Recognition of the 1st International Reference Reagents for hCG-related isoforms by diagnostic immunoassays for hCG: A source of between-method differences” has been submitted for publication.

8.3.19 WG-HbA1c: The IFCC HbA1c Network successfully completed two interlaboratory comparisons (Duesseldorf Studies 1 and 2).

8.3.33 WG-STFT: WG-STFT held a meeting with manufacturers on March 2009.

8.3.35 WG-HbA2: A pilot batch of the secondary reference material has been prepared by IRMM. Some aliquots of this material were analyzed by 3 MS labs, who found them suitable for the analysis by the reference measurement procedure under development.

8.3.36 WG-CDT: The additional minor peaks seen in the MS analysis of the candidate CDT reference material needed further evaluation. Additional studies to further assess the purity of the isolated transferrin fractions, including HPLC with UV/DA detection and isoelectric focusing, were suggested.

8.3.37 WG-SCC: Characterization of a candidate secondary reference material is continuing.

8.3.38 WG-GFRA: A study of creatinine assay specificity is underway including both alkaline picrate and enzymatic assays from the major companies.

8.3.39 WG-SAU: A joint paper from the NKDEP Laboratory Working Group and WG-SAU was published in Clin Chem. A study is underway to compare urine albumin and creatinine measurements among different manufacturers’ routine methods to assess their level of harmonization.

8.3.40 WG-PAPPA: It is planned to start the experimental work for the project after a meeting at Euromedlab 2009 in Innsbruck.

8.3.41 WG-GH: Cooperation with the Growth Hormone Research Society has been established to jointly organize a Workshop on GH Standardization in 2009.


8.3.43 WG-TnI: Major companies have agreed to participate in the pilot cTnI method comparison and commutability study set to start experimental work on the second part of 2009.

8.8 PROJECT PROPOSALS:
The SD approved the project proposal, “WG on Acceptability for Traceability Testing of Patient Results” submitted by R Bais (AU). Aim of the proposal is to define clinically acceptance criteria for traceability of specific analytes.

8.19 MEETINGS
8.19.44 44th SD Meeting, Milan, Italy, October 2-3, 2009
8.19.45 45th SD meeting, Corfu, Greece, April 16-17, 2010